50456-78-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Hydroxydibenzo[b,e]oxepin-11(6H)-one is used as a key intermediate in the synthesis of (E)-2-Hydroxy Doxepin (H941785), which is a metabolite of Doxepin (D550000). Doxepin is a tricyclic antidepressant medication that is used to treat various mental health conditions, such as depression and anxiety disorders. The synthesis of (E)-2-Hydroxy Doxepin through the use of 2-Hydroxydibenzo[b,e]oxepin-11(6H)-one allows for the development of new therapeutic agents and the enhancement of existing treatments.

Upstream product

• 23560-67-0 2-methoxy-6,11-dihydrodibenz[b,e]oxepin-11-one 
• 23560-68-1 2-<(4-Methoxyphenyl)oxymethyl>benzoic acid 
• 872041-16-2 (2-bromomethylphenyl)-(2,5-dihydroxyphenyl)methanone 
• 1122-95-8 sodium 4-methoxyphenolate 
• 87-41-2 2-benzofuran-1(3H)-one 

Downstream Products

• 139305-55-8 (E)-1-(2-Acetoxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine 
• 139305-61-6 (E)-1-(2-Methoxymethyloxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine fumarate 
• 114312-46-8 (E)-1-(2-tert-Butyldimethylsilyloxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine dimaleate 
• 139305-59-2 (E)-1-(2-Benzyloxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine difumarate 
• 114312-26-4 (E)-1-(2-Hydroxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine 
• 139305-56-9 (E)-1-(2-Ethoxy-6,11-dihydrodibenzoxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine 

Relevant academic research and scientific papers

Topical formulations for treating allergic diseases

Methods for topically treating allergic diseases of the eye, ear or nose using tricyclic compounds are disclosed.

QUINOLINE DERIVATIVE

This invention relates to a compound (a quinoline derivative) represented by the formula (I): STR1 The quinoline derivative of this invention has a strong leukotriene antagonistic action and is extremely useful as an antiallergic medicine and an anti-inflammatory medicine.

Synthesis and biological activity of 11-[4-(cinnamyl)-1-piperazinyl]-6,11-dihydrodibenz[b,e]oxepin derivatives, potential agents for the treatment of cerebrovascular disorders

A series of 11-[4-(cinnamyl)-1-piperazinyl]-6,11-dihydrodibenz[b,e]oxepins and related compounds were synthesized and evaluated for their protective activities against complete ischemia, normobaric hypoxia, lipidperoxidation and convulsion. Structure-activity relationship studies of this series led to the finding of (E)-1-(3-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl)-4-(3-phenyl-2-prop enyl)piperazine dimaleate (50), AJ-3941 with the most appropriate property for combined pharmacological activities. Compound 50 also shows an inhibitory effect against cerebral edema as well when orally given to rats.

Dibenz[b,e]oxepin derivatives and pharmaceutical composition containing the same

The present invention relates to compounds represented by the general formula (I): STR1 wherein R1 is H or methoxy, R2 is H, methoxy, OH or F, R3 is H or F, R4 is H or F at 7-, 8- or 9-position, and Ar is a benz